Showing results (231-240 of 277) with videos related to

Sort By:
Pageof 28
Nature Communications|May 20, 2020
Author Correction: Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancerAnniina Färkkilä, Doga C Gulhan, Julia Casado, et al.
The Lancet. Oncology|September 8, 2012
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 studyD Ross Camidge, Yung-Jue Bang, Eunice L Kwak, et al.
Cancer Discovery|May 25, 2016
Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid TumorsAmita Patnaik, Lee S Rosen, Sara M Tolaney, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2017
Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring <i>MET</i> Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical ModelsLars D Engstrom, Ruth Aranda, Matthew Lee, et al.
Cell Reports|November 24, 2016
CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast CancerShawn F Johnson, Cristina Cruz, Ann Katrin Greifenberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2016
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid TumorsPatricia M LoRusso, Jing Li, Angelika Burger, et al.
The Lancet. Oncology|June 20, 2020
Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trialPanagiotis A Konstantinopoulos, Su-Chun Cheng, Andrea E Wahner Hendrickson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2022
A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid TumorsAtish D Choudhury, Celestia S Higano, Johann S de Bono, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 21, 2024
Selective CDK7 Inhibition Suppresses Cell Cycle Progression and MYC Signaling While Enhancing Apoptosis in Therapy-resistant Estrogen Receptor-positive Breast CancerCristina Guarducci, Agostina Nardone, Douglas Russo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 11, 2023
A Phase I Expansion Cohort Study Evaluating the Safety and Efficacy of the CHK1 Inhibitor LY2880070 with Low-dose Gemcitabine in Patients with Metastatic Pancreatic AdenocarcinomaBrandon M Huffman, Hanrong Feng, Kalindi Parmar, et al.
Pageof 28